Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

House dust mite allergy immunotherapy - ALK-Abello

Next Previous
X
Search
Drug Profile

House dust mite allergy immunotherapy - ALK-Abello

Alternative Names: ACARIZAX; ALK HDM; ALK Mite Tablet; HDM AIT; HDM SLIT drops - ALK-Abello; HDM SLIT extract - ALK-Abello; HDM SLIT tablet- ALK-Abello; House dust mite extract - ALK-Abello; House dust mite SLIT drops - ALK-Abello; House dust mite SLIT One Dermatophagoides mixture - ALK-Abello; House dust mite SLIT tablet - ALK-Abello; MITICURE; Mitizax; MK-8237; Odactra; SCH-900237; SLITONEULTRA-HDM; SQ®HDM SLIT-tablet - ALK-Abello; TO-203

Latest Information Update: 07 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ALK-Abello
  • Developer Abbott Laboratories; ALK-Abello; Merck & Co; Seqirus; Torii Pharmaceutical
  • Class Allergens; Allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic asthma; Allergic rhinitis; Allergic rhinoconjunctivitis
  • Phase III Atopic dermatitis; Rhinoconjunctivitis

Most Recent Events

  • 04 Jun 2024 Updated efficacy data from a phase III MATIC trial in Allergic rhinitis released by ALK-Abello
  • 25 Jan 2024 Preregistration for Allergic rhinitis (In children) in European Union (Sublingual)
  • 25 Jan 2024 ALK-Abelló announces intention to submit BLA to US FDA for Allergic rhinitis (In children) (Sublingual, Tablet) in first half of 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top